Autophagy: A Player in response to Oxidative Stress and DNA Damage.


Journal

Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826

Informations de publication

Date de publication:
2019
Historique:
received: 22 02 2019
revised: 07 05 2019
accepted: 10 06 2019
entrez: 31 8 2019
pubmed: 31 8 2019
medline: 28 1 2020
Statut: epublish

Résumé

Autophagy is a catabolic pathway activated in response to different cellular stressors, such as damaged organelles, accumulation of misfolded or unfolded proteins, ER stress, accumulation of reactive oxygen species, and DNA damage. Some DNA damage sensors like FOXO3a, ATM, ATR, and p53 are known to be important autophagy regulators, and autophagy seems therefore to have a role in DNA damage response (DDR). Recent studies have partly clarified the pathways that induce autophagy during DDR, but its precise role is still not well known. Previous studies have shown that autophagy alterations induce an increase in DNA damage and in the occurrence of tumor and neurodegenerative diseases, highlighting its fundamental role in the maintenance of genomic stability. During DDR, autophagy could act as a source of energy to maintain cell cycle arrest and to sustain DNA repair activities. In addition, autophagy seems to play a role in the degradation of components involved in the repair machinery. In this paper, molecules which are able to induce oxidative stress and/or DNA damage have been selected and their toxic and genotoxic effects on the U937 cell line have been assessed in the presence of the single compounds and in concurrence with an inhibitor (chloroquine) or an inducer (rapamycin) of autophagy. Our data seem to corroborate the fundamental role of this pathway in response to direct and indirect DNA-damaging agents. The inhibition of autophagy through chloroquine had no effect on the genotoxicity induced by the tested compounds, but it led to a high increase of cytotoxicity. The induction of autophagy, through cotreatment with rapamycin, reduced the genotoxic activity of the compounds. The present study confirms the cytoprotective role of autophagy during DDR; its inhibition can sensitize cancer cells to DNA-damaging agents. The modulation of this pathway could therefore be an innovative approach able to reduce the toxicity of many compounds and to enhance the activity of others, including anticancer drugs.

Identifiants

pubmed: 31467633
doi: 10.1155/2019/5692958
pmc: PMC6701339
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5692958

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

J Nat Prod. 2000 Jan;63(1):158-68
pubmed: 10650103
Mutagenesis. 2002 Nov;17(6):489-93
pubmed: 12435846
Dev Cell. 2004 Apr;6(4):463-77
pubmed: 15068787
Mol Cell Biol. 2005 Feb;25(3):1025-40
pubmed: 15657430
Oncology (Williston Park). 2004 Dec;18(14 Suppl 11):14-21
pubmed: 15688598
Br J Pharmacol. 2006 Feb;147(3):239-48
pubmed: 16331284
Nat Rev Cancer. 2006 Oct;6(10):813-23
pubmed: 16990858
J Biol Chem. 2006 Dec 29;281(52):40485-92
pubmed: 17088248
Leukemia. 2007 Apr;21(4):838-42
pubmed: 17268529
Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G296-307
pubmed: 17431216
Genes Dev. 2007 Jul 1;21(13):1621-35
pubmed: 17606641
Int J Oncol. 2007 Aug;31(2):323-31
pubmed: 17611688
Am J Pathol. 2007 Aug;171(2):513-24
pubmed: 17620365
Methods Mol Biol. 2008;445:29-76
pubmed: 18425442
Biochem Biophys Res Commun. 2008 Sep 19;374(2):258-63
pubmed: 18638451
Free Radic Res. 2008 Aug;42(8):689-706
pubmed: 18671159
Cancer Chemother Pharmacol. 2009 Dec;65(1):143-50
pubmed: 19449007
Cell. 2009 Jun 12;137(6):1062-75
pubmed: 19524509
Toxicol Lett. 2009 Nov 12;190(3):254-65
pubmed: 19857796
Oncogene. 2010 Jan 21;29(3):451-62
pubmed: 19881538
FEBS Lett. 2010 Apr 2;584(7):1287-95
pubmed: 20083114
Free Radic Biol Med. 2010 Dec 15;49(12):1925-36
pubmed: 20937380
J Parasitol Res. 2009;2009:463575
pubmed: 20981287
Autophagy. 2011 May;7(5):457-65
pubmed: 21150268
Nature. 2011 Mar 3;471(7336):74-79
pubmed: 21368826
Mutat Res. 2011 Jun 3;711(1-2):158-66
pubmed: 21419786
Br J Nutr. 2012 May;107(9):1324-32
pubmed: 22088277
Ann Hematol. 2012 Jun;91(6):847-56
pubmed: 22231280
J Biol Chem. 2012 Apr 6;287(15):12455-68
pubmed: 22362782
Autophagy. 2012 Sep;8(9):1371-82
pubmed: 22895056
Annu Rev Pathol. 2013 Jan 24;8:105-37
pubmed: 23072311
Anat Rec (Hoboken). 2013 Jan;296(1):31-9
pubmed: 23125185
Cell Div. 2012 Dec 26;7(1):26
pubmed: 23268747
Mutat Res. 1990 May;230(1):81-91
pubmed: 2342500
PLoS One. 2013 Jun 07;8(6):e65181
pubmed: 23762310
Cell Death Differ. 2013 Nov;20(11):1444-54
pubmed: 23933813
Autophagy. 2013 Oct;9(10):1500-8
pubmed: 23934082
Nat Rev Mol Cell Biol. 2014 Feb;15(2):81-94
pubmed: 24401948
Metallomics. 2014 Apr;6(4):783-92
pubmed: 24535170
PLoS One. 2014 Jul 25;9(7):e103364
pubmed: 25062253
Biochim Biophys Acta. 2015 Jan;1853(1):14-26
pubmed: 25284725
Int J Mol Sci. 2015 Jan 23;16(2):2641-62
pubmed: 25625517
Sci Rep. 2015 Jul 21;5:12362
pubmed: 26197097
Biotechnol Lett. 2016 Feb;38(2):357-65
pubmed: 26423802
Chem Biol Interact. 2016 Mar 5;247:1-10
pubmed: 26800624
Int J Oncol. 2016 Jun;48(6):2558-66
pubmed: 27035631
Mol Cell. 2016 Jul 7;63(1):34-48
pubmed: 27345151
Cancer Sci. 2016 Nov;107(11):1610-1621
pubmed: 27560771
Oncotarget. 2016 Nov 22;7(47):76496-76507
pubmed: 27738311
Trends Cell Biol. 2017 May;27(5):340-351
pubmed: 28011061
Redox Biol. 2017 Apr;11:219-230
pubmed: 28012437
Food Chem Toxicol. 2017 Jul;105:498-505
pubmed: 28483535
Leuk Res. 2017 Sep;60:44-52
pubmed: 28651104
Essays Biochem. 2017 Dec 12;61(6):565-584
pubmed: 29233869
Front Oncol. 2018 Mar 16;8:73
pubmed: 29616191
Cancer Cell Int. 2018 Apr 24;18:63
pubmed: 29713246
Oncotarget. 2018 May 4;9(34):23780-23823
pubmed: 29805774
BMC Cancer. 2018 Aug 6;18(1):791
pubmed: 30081901
J Cell Sci. 2018 Sep 20;131(18):null
pubmed: 30237248
Arch Pharm Res. 2018 Nov;41(11):1062-1073
pubmed: 30264324
Nat Commun. 2018 Oct 8;9(1):4139
pubmed: 30297842
J Oncol Pharm Pract. 2019 Oct;25(7):1638-1644
pubmed: 30319063
Br J Cancer. 2018 Oct;119(9):1044-1051
pubmed: 30356125
Sci Signal. 2018 Dec 04;11(559):null
pubmed: 30514809
J Cell Biochem. 2019 Jun;120(6):10662-10669
pubmed: 30652348
Mutat Res. 1984 Sep-Nov;134(2-3):113-42
pubmed: 6390190
Mutat Res. 1994 Apr 1;306(1):19-34
pubmed: 7512200
Mutat Res. 1994 Sep;315(2):169-79
pubmed: 7520998

Auteurs

Serena Galati (S)

Centre for Molecular and Translational Oncology-COMT, University of Parma, Parma 43124, Italy.
Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma 43124, Italy.

Christian Boni (C)

Department of Medicine, General Pathology Section, University of Verona, Verona 37134, Italy.

Maria Carla Gerra (MC)

Department of Health Science and Technology, University of Aalborg, Aalborg 9220, Denmark.

Mirca Lazzaretti (M)

Centre for Molecular and Translational Oncology-COMT, University of Parma, Parma 43124, Italy.
Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma 43124, Italy.

Annamaria Buschini (A)

Centre for Molecular and Translational Oncology-COMT, University of Parma, Parma 43124, Italy.
Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma 43124, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH